163 related articles for article (PubMed ID: 32096678)
1. Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
Saad F; Fleshner N; Pickles T; Niazi T; Lukka H; Pouliot F; Martins I; Klotz L
J Urol; 2020 Sep; 204(3):416-426. PubMed ID: 32096678
[TBL] [Abstract][Full Text] [Related]
2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
3. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
[TBL] [Abstract][Full Text] [Related]
4. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Nishiyama T
Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice.
Sayyid RK; Sayyid AK; Klaassen Z; Fadaak K; Goldberg H; Chandrasekar T; Ahmad A; Leao R; Perlis N; Chadwick K; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta AR; Fleshner NE
J Urol; 2018 Jan; 199(1):251-256. PubMed ID: 28751266
[TBL] [Abstract][Full Text] [Related]
6. Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
Morote J; Comas I
J Urol; 2021 Feb; 205(2):343-345. PubMed ID: 33026925
[No Abstract] [Full Text] [Related]
7. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F
Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
[TBL] [Abstract][Full Text] [Related]
8. Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
Regis L; Planas J; Carles J; Maldonado X; Comas I; Ferrer R; Morote J
Prostate; 2017 Jan; 77(1):114-120. PubMed ID: 27800640
[TBL] [Abstract][Full Text] [Related]
9. Testosterone in prostate cancer: the Bethesda consensus.
Djavan B; Eastham J; Gomella L; Tombal B; Taneja S; Dianat SS; Kazzazi A; Shore N; Abrahamsson PA; Cheetham P; Moul J; Lepor H; Crawford ED
BJU Int; 2012 Aug; 110(3):344-52. PubMed ID: 22129242
[TBL] [Abstract][Full Text] [Related]
10. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.
Klotz L; O'Callaghan C; Ding K; Toren P; Dearnaley D; Higano CS; Horwitz E; Malone S; Goldenberg L; Gospodarowicz M; Crook JM
J Clin Oncol; 2015 Apr; 33(10):1151-6. PubMed ID: 25732157
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer and androgen deprivation: optimal castration? Prospects and developments.
Boccafoschi C
Arch Ital Urol Androl; 2011 Mar; 83(1):63-6. PubMed ID: 21585175
[TBL] [Abstract][Full Text] [Related]
12. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
[TBL] [Abstract][Full Text] [Related]
13. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
14. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
[TBL] [Abstract][Full Text] [Related]
16. The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial.
Dosani M; Morris WJ; Tyldesley S; Pickles T
Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):696-701. PubMed ID: 28712786
[TBL] [Abstract][Full Text] [Related]
17. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
Pascal LE; Masoodi KZ; O'Malley KJ; Shevrin D; Gingrich JR; Parikh RA; Wang Z
J Urol; 2015 Apr; 193(4):1388-93. PubMed ID: 25444984
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
19. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
20. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Int J Biol Markers; 2005; 20(2):119-22. PubMed ID: 16011042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
